Our aim is to revolutionize care for people and planet. We drive change that improves the health and wellbeing of patients and those who care for them – while reducing the environmental footprint of healthcare and the life sciences.
Sterile, blue cleanroom undergloves with beaded cuffs and curved fingers are made to be worn in combination with the Biogel™ PI Micro Tech overglove to form a breach indication system. The gloves are suitable for use in aseptic and Class 100 (ISO 5) / EU GMP Grade A environments.
Sterile, blue cleanroom undergloves with beaded cuffs and curved fingers are made to be worn in combination with the Biogel™ PI Tech overglove to form a breach indication system. The gloves are suitable for use in aseptic and Class 100 (ISO 5) / EU GMP Grade A environments.
Sterile, cleanroom gloves with beaded anti-slip cuffs and curved fingers are suitable for use in aseptic and Class 100 (ISO 5) / EU GMP Grade A environments. Adviced to be worn in combination with the Biogel™ PI Tech Indicator Underglove to form a breach indication system.
Sterile, cleanroom gloves with beaded anti-slip cuffs and curved fingers are suitable for use in aseptic and Class 100 (ISO 5) / EU GMP Grade A environments. Adviced to be worn in combination with the Biogel™ PI Micro Tech Indicator Underglove to form a breach indication system.
Sterile, blue cleanroom undergloves with beaded cuffs and curved fingers are made to be worn in combination with the Biogel™ NeoTech overglove to form a breach indication system. The gloves are suitable for use in aseptic and Class 100 (ISO 5) / EU GMP Grade A environments.
Sterile cleanroom gloves with beaded cuffs and curved fingers are suitable for use in aseptic and Class 100 (ISO 5) / EU GMP Grade A environments. Adviced to be worn in combination with the Biogel™ NeoTech Indicator™ Underglove to form a breach indication system.
Sterile durable all-purpose critical environment glove. It offers excellent barrier protection as well as fit, feel and comfort . It has been tested and cleared for use with chemotherapy agents.
Innovation is at the core of who we are as a company. Mölnlycke has been at the forefront of change since 1849, pioneering innovations that improve the quality of life for patients and those who care for them, while reducing the environmental impact of healthcare and the life sciences. We partner with those seeking to shape the future of care, not only to solve the problems of today, but also to address the challenges of tomorrow. Moving forward we will draw upon our proud legacy as we continue to revolutionize care for people and planet.
Mölnlycke employs over 8,000 people. The company headquarters are in Gothenburg, Sweden and we operate in more than 100 countries worldwide. Since 2007, the company has been part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916.
